Methanesulfonic acid deferoxamine adjuvant and vaccine comprising methanesulfonic acid deferoxamine adjuvant

A technology of deferoxamine mesylate and vaccine, applied in the field of immunology, can solve problems such as high price, toxic and side effects, and achieve the effects of low cost, small toxic and side effects, and enhancing humoral immune response

Active Publication Date: 2014-04-23
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to solve the problems of toxic and side effects and high price in existing vaccine adjuvants, the present invention provides a safe, effective, stable and economical deferoxamine mesylate adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methanesulfonic acid deferoxamine adjuvant and vaccine comprising methanesulfonic acid deferoxamine adjuvant
  • Methanesulfonic acid deferoxamine adjuvant and vaccine comprising methanesulfonic acid deferoxamine adjuvant
  • Methanesulfonic acid deferoxamine adjuvant and vaccine comprising methanesulfonic acid deferoxamine adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The dosage of deferoxamine mesylate adjuvant provided in this example is 1 mg.

[0023] The hepatitis A vaccine containing deferoxamine mesylate adjuvant provided in this example is: in each single portion of HAV antigen (that is, the single injection dose used in animal experiment mice), add 1 mg of deferoxamine mesylate adjuvant Add normal saline to 200ul, and mix according to routine to obtain the hepatitis A vaccine containing deferoxamine mesylate adjuvant, wherein, deferoxamine mesylate is a commercially available product, purchased from Novartis Pharmaceuticals Co., Ltd., Switzerland, HAV antigen The commercially available 18EU HAV antigen solution with an antigen titer of 512EU / ml was purchased from the Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College.

[0024] The immune test and effect of the hepatitis A vaccine containing deferoxamine mesylate adjuvant obtained in present embodiment 1 are as follows:

[0025]...

Embodiment 2

[0041] The dosage of deferoxamine mesylate adjuvant provided in this example is 4 mg.

[0042] Add 4 mg of deferoxamine mesylate adjuvant to each single portion of HAV antigen (that is, the single injection dose used in animal experiment mice), add normal saline to 200ul, and mix according to routine to obtain desferoxamine mesylate adjuvant The hepatitis A vaccine of iron amine adjuvant, wherein, deferoxamine mesylate, HAV antigen are with embodiment 1;

[0043] The immune test of the hepatitis A vaccine containing deferoxamine mesylate adjuvant obtained in Example 2 is the same as in Example 1, and the results are shown in Table 2.

[0044] Table 2 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 2.

[0045] Table 2

[0046]

[0047]Through data analysis, it can be seen that from the 4th week after immunization, all experimental groups except the blank group can produce anti-HAV ...

Embodiment 3

[0049] The dosage of deferoxamine mesylate adjuvant provided in this example is 8 mg.

[0050] Add 8 mg of deferoxamine mesylate adjuvant to each single dose of HAV antigen (that is, the single injection dose used in animal experiment mice), add normal saline to 200ul, and mix according to routine to obtain desferrioxamine mesylate adjuvant The hepatitis A vaccine of iron amine adjuvant, wherein, deferoxamine mesylate, HAV antigen are with embodiment 1;

[0051] The immune test of the hepatitis A vaccine containing deferoxamine mesylate adjuvant obtained in Example 3 is the same as in Example 1, and the effects are shown in Table 3.

[0052] Table 3 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 3.

[0053] table 3

[0054]

[0055] Through data analysis, it can be seen that from the 4th week after immunization, all experimental groups except the blank group can produce anti-HAV ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a methanesulfonic acid deferoxamine adjuvant and a vaccine comprising the methanesulfonic acid deferoxamine adjuvant. A single part of the vaccine comprising the methanesulfonic acid deferoxamine adjuvant comprises 0.6-8mg methanesulfonic acid deferoxamine adjuvant. The methanesulfonic acid deferoxamine adjuvant is applied to clinical treatment for a long term, has small toxic and side effects, is safe and reliable to use within an immunizing dose scope, and can effectively induce antigen-specific humoral immunity response, the induced humoral immunity response effect is better than that of a group without the adjuvant, a raw material of the methanesulfonic acid deferoxamine adjuvant is easy to obtain and is a marketed product, and the methanesulfonic acid deferoxamine adjuvant is simple in preparation technology, low in cost and stable in performance, and can be added to various traditional vaccines and genetic engineering vaccines as a vaccine adjuvant.

Description

[0001] technical field [0002] The invention relates to a deferoxamine mesylate adjuvant and a vaccine containing the adjuvant, belonging to the technical field of immunology. Background technique [0003] In recent years, with the continuous deepening of vaccine research, especially the rapid development of molecular biotechnology, new genetic engineering vaccines have been developed with high purity and strong specificity, but small molecules and relatively weak immunogenicity make it difficult to produce effective immunity. answer. Therefore, it is particularly important to use adjuvants to enhance its immunogenicity. [0004] At present, there are still very few adjuvants that have been approved for use in humans, and aluminum salt adjuvants are one of them. Aluminum salt adjuvants have been proven to improve antibody levels and safety for a long time, but due to their shortcomings such as causing allergies and inducing degenerative neuropathy, there is an urgent need...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/205A61K39/29A61P37/04
CPCY02A50/30
Inventor 胡凝珠罗婷王海漩胡云章李彦涵李建芳
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap